vs
ICF International, Inc.（ICFI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ICF International, Inc.的1.4倍（$622.0M vs $443.7M），Royalty Pharma plc净利率更高（34.4% vs 3.9%，领先30.5%），Royalty Pharma plc同比增速更快（4.8% vs -10.6%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -5.3%）
ICF International是一家总部位于美国弗吉尼亚州雷斯顿的上市企业，主营咨询与技术服务，为各行业客户提供专业的解决方案支持，业务覆盖多领域的专业咨询及技术落地服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ICFI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.4倍
$443.7M
营收增速更快
RPRX
高出15.4%
-10.6%
净利率更高
RPRX
高出30.5%
3.9%
两年增速更快
RPRX
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $443.7M | $622.0M |
| 净利润 | $17.3M | $214.2M |
| 毛利率 | 35.7% | — |
| 营业利润率 | 6.5% | 62.4% |
| 净利率 | 3.9% | 34.4% |
| 营收同比 | -10.6% | 4.8% |
| 净利润同比 | -29.5% | 2.9% |
| 每股收益（稀释后） | $0.95 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICFIRPRX
| Q4 25 | $443.7M | $622.0M | ||
| Q3 25 | $465.4M | $609.3M | ||
| Q2 25 | $476.2M | $578.7M | ||
| Q1 25 | $487.6M | $568.2M | ||
| Q4 24 | $496.3M | $593.6M | ||
| Q3 24 | $517.0M | $564.7M | ||
| Q2 24 | $512.0M | $537.3M | ||
| Q1 24 | $494.4M | $568.0M |
净利润ICFIRPRX
| Q4 25 | $17.3M | $214.2M | ||
| Q3 25 | $23.8M | $288.2M | ||
| Q2 25 | $23.7M | $30.2M | ||
| Q1 25 | $26.9M | $238.3M | ||
| Q4 24 | $24.6M | $208.2M | ||
| Q3 24 | $32.7M | $544.0M | ||
| Q2 24 | $25.6M | $102.0M | ||
| Q1 24 | $27.3M | $4.8M |
毛利率ICFIRPRX
| Q4 25 | 35.7% | — | ||
| Q3 25 | 37.6% | — | ||
| Q2 25 | 37.3% | — | ||
| Q1 25 | 38.0% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 37.1% | — | ||
| Q2 24 | 35.7% | — | ||
| Q1 24 | 37.2% | — |
营业利润率ICFIRPRX
| Q4 25 | 6.5% | 62.4% | ||
| Q3 25 | 8.3% | 70.1% | ||
| Q2 25 | 8.4% | 36.3% | ||
| Q1 25 | 7.9% | 94.0% | ||
| Q4 24 | 7.3% | 60.9% | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 8.3% | 50.2% | ||
| Q1 24 | 8.3% | -13.0% |
净利率ICFIRPRX
| Q4 25 | 3.9% | 34.4% | ||
| Q3 25 | 5.1% | 47.3% | ||
| Q2 25 | 5.0% | 5.2% | ||
| Q1 25 | 5.5% | 41.9% | ||
| Q4 24 | 4.9% | 35.1% | ||
| Q3 24 | 6.3% | 96.3% | ||
| Q2 24 | 5.0% | 19.0% | ||
| Q1 24 | 5.5% | 0.8% |
每股收益（稀释后）ICFIRPRX
| Q4 25 | $0.95 | $0.49 | ||
| Q3 25 | $1.28 | $0.67 | ||
| Q2 25 | $1.28 | $0.07 | ||
| Q1 25 | $1.44 | $0.55 | ||
| Q4 24 | $1.29 | $0.46 | ||
| Q3 24 | $1.73 | $1.21 | ||
| Q2 24 | $1.36 | $0.23 | ||
| Q1 24 | $1.44 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3M | $618.7M |
| 总债务越低越好 | $401.4M | $9.0B |
| 股东权益账面价值 | $1.0B | $9.7B |
| 总资产 | $2.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.39× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ICFIRPRX
| Q4 25 | $5.3M | $618.7M | ||
| Q3 25 | $4.0M | $938.9M | ||
| Q2 25 | $7.0M | $631.9M | ||
| Q1 25 | $5.7M | $1.1B | ||
| Q4 24 | $5.0M | $929.0M | ||
| Q3 24 | $6.9M | $950.1M | ||
| Q2 24 | $4.1M | $1.8B | ||
| Q1 24 | $3.7M | $843.0M |
总债务ICFIRPRX
| Q4 25 | $401.4M | $9.0B | ||
| Q3 25 | $449.4M | $8.9B | ||
| Q2 25 | $462.3M | $8.0B | ||
| Q1 25 | $502.0M | $7.6B | ||
| Q4 24 | $411.7M | $7.6B | ||
| Q3 24 | $419.1M | $7.6B | ||
| Q2 24 | $433.9M | $7.6B | ||
| Q1 24 | $474.7M | $6.1B |
股东权益ICFIRPRX
| Q4 25 | $1.0B | $9.7B | ||
| Q3 25 | $1.0B | $9.6B | ||
| Q2 25 | $1.0B | $9.5B | ||
| Q1 25 | $968.9M | $9.8B | ||
| Q4 24 | $982.5M | $10.3B | ||
| Q3 24 | $976.3M | $10.3B | ||
| Q2 24 | $943.3M | $9.8B | ||
| Q1 24 | $916.1M | $9.9B |
总资产ICFIRPRX
| Q4 25 | $2.1B | $19.6B | ||
| Q3 25 | $2.1B | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.1B | $18.2B | ||
| Q3 24 | $2.0B | $18.0B | ||
| Q2 24 | $2.0B | $17.7B | ||
| Q1 24 | $2.0B | $16.1B |
负债/权益比ICFIRPRX
| Q4 25 | 0.39× | 0.92× | ||
| Q3 25 | 0.44× | 0.93× | ||
| Q2 25 | 0.46× | 0.84× | ||
| Q1 25 | 0.52× | 0.78× | ||
| Q4 24 | 0.42× | 0.74× | ||
| Q3 24 | 0.43× | 0.74× | ||
| Q2 24 | 0.46× | 0.78× | ||
| Q1 24 | 0.52× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.6M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $68.7M | — |
| 自由现金流率自由现金流/营收 | 15.5% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | 4.37× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $120.2M | — |
8季度趋势，按日历期对齐
经营现金流ICFIRPRX
| Q4 25 | $75.6M | $827.1M | ||
| Q3 25 | $47.3M | $702.6M | ||
| Q2 25 | $52.0M | $364.0M | ||
| Q1 25 | $-33.0M | $596.1M | ||
| Q4 24 | $95.4M | $742.5M | ||
| Q3 24 | $25.5M | $703.6M | ||
| Q2 24 | $60.6M | $658.2M | ||
| Q1 24 | $-10.0M | $664.6M |
自由现金流ICFIRPRX
| Q4 25 | $68.7M | — | ||
| Q3 25 | $41.8M | — | ||
| Q2 25 | $46.2M | — | ||
| Q1 25 | $-36.5M | — | ||
| Q4 24 | $89.5M | — | ||
| Q3 24 | $20.4M | — | ||
| Q2 24 | $55.5M | — | ||
| Q1 24 | $-15.2M | — |
自由现金流率ICFIRPRX
| Q4 25 | 15.5% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | -7.5% | — | ||
| Q4 24 | 18.0% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 10.8% | — | ||
| Q1 24 | -3.1% | — |
资本支出强度ICFIRPRX
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 1.1% | — |
现金转化率ICFIRPRX
| Q4 25 | 4.37× | 3.86× | ||
| Q3 25 | 1.99× | 2.44× | ||
| Q2 25 | 2.20× | 12.06× | ||
| Q1 25 | -1.23× | 2.50× | ||
| Q4 24 | 3.88× | 3.57× | ||
| Q3 24 | 0.78× | 1.29× | ||
| Q2 24 | 2.37× | 6.45× | ||
| Q1 24 | -0.37× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICFI
| US Federal Government | $166.7M | 38% |
| Commercial | $164.4M | 37% |
| US State And Local Government | $78.7M | 18% |
| International Government | $33.8M | 8% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
